ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 1115 • 2018 ACR/ARHP Annual Meeting

    In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis

    Emma C. Derrett-Smith1,2, Shiwen Xu1, David Abraham3, Olivier Lacombe4, Pierre Broqua4, Jean-Louis Junien4, Irena Konstantinova5 and Christopher P. Denton6, 1Division of Medicine, University College London, London, United Kingdom, 2Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 3Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, 4Inventiva, DAIX, France, 5Inventiva, Daix, France, 6University College London, London, United Kingdom

    Background/Purpose: The TbRIIDk-fib transgenic (TG) mouse model of scleroderma carries a fibroblast-specific transforming growth factor β (TGFβ) receptor II mutation resulting in balanced up-regulation of…
  • Abstract Number: 392 • 2017 ACR/ARHP Annual Meeting

    Effects of Synthetic Dmards on the Insulin Resistance and Obesity Associated with Rheumatoid Arthritis: An Obese Mouse Model of Arthritis

    Nuria Barbarroja1, Ivan Arias de la Rosa2, Miriam Ruiz-Ponce1, Sergio Rodriguez-Cuenca3, Maria Carmen Abalos-Aguilera2, Yolanda Jiménez-Gómez1, Patricia Ruiz-Limon2, Carlos Perez-Sanchez1, Eduardo Collantes-Estévez1, Antonio Vidal-Puig3, Alejandro Escudero-Contreras2 and Chary Lopez-Pedrera1, 1Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbroke’s Hospital, University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Numerous studies have demonstrated the closely association between rheumatoid arthritis (RA) and metabolic complications such as obesity and insulin resistance (IR). Thus, there is…
  • Abstract Number: 1074 • 2017 ACR/ARHP Annual Meeting

    High Cholesterol Levels By ApoE Defenciency Reduce Bone Destruction in Murine Antigen-Induced Arthritis Via Inhibition of Osteoclastogenesis

    Giuliana Ascone1, Irene Di Ceglie1, Arjen B. Blom1, Birgitte Walgreen2, Annet W. Sloetjes1, Peter M. van der Kraan1, Ernst Lindhout3, Mike Martens3 and Peter L. van Lent4, 1Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 2Experimental, Radboud university medical center, Nijmegen, Netherlands, 3Future Diagnostics Solutions (FDs), Wijchen, Netherlands, 4Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by immune complex- deposition in the synovium, leading to increased bone destruction. In RA, joint…
  • Abstract Number: 1793 • 2017 ACR/ARHP Annual Meeting

    Interleukin-17 Is Not a Determinant for the Pro- or Anti-Inflammatory Character of Interleukin-22 in Experimental Arthritis

    Debbie M. Roeleveld1, Loreto Parga Vidal2, Monique M. Helsen2, Birgitte Walgreen3, Bianka Marklein4, Karl Skriner5, Martin Hegen6, Peter L. van Lent2, Fons A.J. van de Loo2, Wim B. van den Berg2, Peter M. van der Kraan2 and Marije I. Koenders2, 1Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Experimental, Radboud university medical center, Nijmegen, Netherlands, 4Humboldt University and Free University, Berlin, Germany, 5Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, 6Inflammation and Immunology Research Unit, Pfizer, Cambridge, MA

    Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
  • Abstract Number: 393 • 2017 ACR/ARHP Annual Meeting

    The Role of Follicular Helper 17 T Cells in Glucose-6-Phosphate Isomerase Induced Arthritis

    Izumi Kurata, Isao Matsumoto, Atsumu Osada, Hiroshi Ebe, Hoshimi Kawaguchi, Yuya Kondo, Hiroto Tsuboi and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: Follicular helper T (Tfh) cell is a novel T cell subset which promotes follicular B cell activation, differentiation to plasma cell and antibody production.…
  • Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting

    TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases

    Hiroaki Hayashi, Ryuusuke Kaneko, Manabu Tayama, Shunsuke Demizu, Daichi Akasaka, Hiroki Irie, Aki Kawagishi, Yoshio Ogino, Teruhiro Utsugi, Eiji Sasaki and Yoshikazu Iwasawa, TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

    Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…
  • Abstract Number: 1794 • 2017 ACR/ARHP Annual Meeting

    Overexpression of Interleuk-22 Induces Expression of the Negative Immune-Regulator SOCS3 and Potently Reduces Collagen-Induced Arthritis in Mice

    Debbie M. Roeleveld1, Monique M. Helsen2, Birgitte Walgreen3, Elly Vitters2, Fons A.J. van de Loo2, Peter L. van Lent2, Wim B. van den Berg2, Peter M. van der Kraan2 and Marije I. Koenders2, 1Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Experimental, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: High interleukin-22 (IL-22) levels are detected in serum and synovial fluid of rheumatoid arthritis (RA) patients and have been shown to positively correlate with…
  • Abstract Number: 394 • 2017 ACR/ARHP Annual Meeting

    Female Tumor Necrosis Factor Transgenic Mice Have More Severe Arthritis Than Males and Supporessed Levels of Bifidobacterium Pseudolongum in Their Gut Microbiome

    Emily Wu1, Richard Bell2, Alex Grier3, Steven Gill4, Edward Schwarz5 and Homaira Rahimi6, 1Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 2Center for Musculoskelatal Research, University of Rochester, Rochester, NY, 3Rochester Genomics Center, University of Rochester, Rochester, NY, 4Genomics Research Center, University of Rochester, Rochester, NY, 5Orthopedeatrics, University of Rochester, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) has an increased prevalence and severity in women compared to men, yet the underlying etiology of this sexual dimorphism is unknown.…
  • Abstract Number: 1320 • 2017 ACR/ARHP Annual Meeting

    TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Ameliorates Inflammation and Bone Erosion in Murine Model for Rheumatoid Arthritis

    Yohei Yoshiga1, Fumihito Hosoi1, Satoru Iguchi1, Ryuusuke Kaneko2, Yoshinori Nakachi1, Daichi Akasaka2, Kenji Tanaka2, Kazuhiko Yonekura2, Teruhiro Utsugi2, Eiji Sasaki2 and Yoshikazu Iwasawa2, 1TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, 2TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

    Background/Purpose: The erosions of bone and cartilage are a cardinal feature of rheumatoid arthritis (RA) and associated with disease severity and poor functional outcome. Although…
  • Abstract Number: 1833 • 2017 ACR/ARHP Annual Meeting

    iRhom2 Deficiency Protects Fcgr2b-/- Lupus-Prone Mice from Kidney Damage By Modulating ADAM17-Dependent Shedding of TNF-α and EGFR Ligand

    Xiaoping Qing1, Yurii Chinenov2, Patricia M. Redecha3, Michael Madaio4, Priya Issuree5, David McIlwain6, Tak Mak7, Carl Blobel5 and Jane E. Salmon8, 1Program in Inflammation and Autoimmunity, Hospital for Special Surgery, New York, NY, 2Arthritis & Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, 3Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, 4Medicine, Medical College of Georgia, Augusta, GA, 5Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY, 6Department of Microbiology and Immunology, Stanford University, Stanford, CA, 7Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Center, Toronto, ON, Canada, 8Medicine/Rheumatology, Hospital of Special Surgery, New York, NY

    Background/Purpose: A disintegrin and metalloprotease 17 (ADAM17) controls ecto-domain shedding of TNFα and epithelial-growth factor ligands (EGFR) such as heparin-binding EGF (HB-EGF).  TNFa and HB-EGF…
  • Abstract Number: 396 • 2017 ACR/ARHP Annual Meeting

    Phospho-STAT1 Inhibition Is the Initial Step after Tofacitinib Treatment in Rabbits with Severe Chronic Synovitis

    Sandra Pérez-Baos, Paula Gratal, Juan Ignacio Barrasa, Ana Lamuedra, Gabriel Herrero-Beaumont and Raquel Largo, Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain

    Background/Purpose: Tofacitinib (TOFA) is a Janus Kinase (Jak) inhibitor approved for the treatment of rheumatoid arthritis (RA) 1. It has recently been shown to selectively…
  • Abstract Number: 1323 • 2017 ACR/ARHP Annual Meeting

    Crucial Roles for Toll-like Receptor 9 in the Pathogenesis of Erosive Autoimmune Arthritis and during Osteoclastogenesis

    Anita Fischer1, Brigitte Meyer1, Birgit Niederreiter2, Erik Lönnblom3, Rikard Holmdahl4 and Günter Steiner2, 1Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Rheumatology, Medical University of Vienna, Vienna, Austria, 3Department of Medical Biochemistry & Biophysics, Karolinska Institute, Stockholm, Sweden, 4Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden

    Background/Purpose: Release and insufficient removal of endogenous nucleic acids may be involved in triggering harmful autoimmune reactions important in the initiation of systemic autoimmune diseases…
  • Abstract Number: 1910 • 2017 ACR/ARHP Annual Meeting

    ERAP1 Deficiency Implicates Long Peptides in Protection from HLA-B27-Induced Experimental Spondyloarthritis

    Tri Tran1, Tejpal Gill1, Joshua R. Bennett1, Vance Holt1, Sohee Hong2, Joel Taurog3 and Robert Colbert1, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2National Institutes of Arthritis and Muskuloskeletal and skin diseases, National Institutes of Health, Bethesda, MD, 3Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Common endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1) haplotypes influence the risk of developing axial spondyloarthritis (SpA) in HLA-B27-positive individuals, with loss-of-function and reduced expression…
  • Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting

    An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis

    Jing Yan1, Nitin Joshi2, Seth Levy2, Sachin Bhagchandani2, Kai Slaughter2, Nicholas Sherman1, Julian Amirault2, Xueyin He2, Tan Shi Rui2, Michael Valic2, Praveen Vemula3, Oscar Miranda2, Oren Levy2, Antonios Aliprantis4, Joerg Ermann1 and Jeffrey Karp2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, 4Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
  • Abstract Number: 1324 • 2017 ACR/ARHP Annual Meeting

    Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction of hTNF-Transgenic Arthritis Mice

    Takafumi Mito1, Tomoyuki Mukai1, Shunichi Fujita1, Shoko Kodama1, Akiko Nagasu1, Teruki Sone2 and Yoshitaka Morita1, 1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, 2Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan

    Background/Purpose: Angiotensin II (Ang II) is known to function on various organs including kidneys, adrenal glands as well as the nervous and cardiovascular systems through…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology